Gilead stock


Gilead Sciences, Inc. (GILD) Presents Phase 3 Clinical Data in HIV-1 at IDWeek 2017

Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts